Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Thymus Neoplasms × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 15 Carcinoma, Renal Cell 8 Neuroendocrine Tumors 6 Neoplasm Metastasis 3 Kidney Neoplasms 3 Tuberous Sclerosis 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma 2 Carcinoid Tumor 2 von Hippel-Lindau Disease 1 Tuberous Sclerosis Complex-associated Refractory Seizures 1 Thymus Neoplasms 1 Stomach Diseases 1 Skin Neoplasms 1 Seizures 1 Renal Cell Cancer Metastatic 1 Prostatic Neoplasms 1 Primary Non-metastatic Breast Cancer 1 Polycystic Kidney, Autosomal Dominant 1 Malignant Carcinoid Syndrome 1 HER2+ Breast Cancer 1 Fibrosis 1 Digestive System Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Cysts 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1

Interventions

Everolimus 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918302 2026-03-06

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡